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Short title: IMMY CrAgSQ Evaluation 29 
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Short summary: The novel semi-quantitative CrAgSQ cryptococcal antigen (CrAg) test had high 31 
sensitivity and specificity compared to current CrAg lateral flow assay and provided quantitative CrAg 32 
results which were associated with both CrAg titers derived from dilutional testing and clinical 33 
outcomes.  34 
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ABSTRACT  44 
Background: Higher cryptococcal antigen (CrAg) titers are strongly associated with mortality risk in 45 
individuals with HIV-associated cryptococcal disease. Rapid tests to quantify CrAg level may provide 46 
important prognostic information and enable treatment stratification. 47 
 48 
Methods: We performed a laboratory-based validation of the semi-quantitative IMMY CrAgSQ assay 49 
against the current gold-standard CrAg tests. We assessed diagnostic accuracy of the CrAgSQ in HIV-50 
positive individuals undergoing CrAg screening; determined the relationship between CrAgSQ scores and 51 
dilutional CrAg titers; assessed inter-rater reliability; and determined clinical correlates of CrAgSQ 52 
scores. 53 
 54 
Results: A total of 872 plasma samples were tested using both CrAgSQ and conventional IMMY CrAg LFA 55 
tests; 692 sequential samples from HIV-positive individuals undergoing CrAg screening and an additional 56 
180 known CrAg-positive plasma samples archived from prior studies. Inter-rater agreement in CrAgSQ 57 
reading was excellent (98.17% agreement, Cohen’s Kappa 0.962, p<0.001). Using IMMY LFA as a 58 
reference standard, CrAgSQ was 93.0% sensitive (95% confidence interval [CI] 80.9%-98.5%) and 93.8% 59 
specific (95%CI 91.7%-95.6%). After reclassification of discordant results using CrAg enzyme 60 
immunoassay testing, sensitivity was 98.1% (95%CI 90.1%-100%), and specificity 95.8% (95%CI 99.1%- 61 
100%). Median CrAg titers were 1:10 (IQR 1:5-1:20) in the CrAgSQ1+ category; 1:40 (IQR 1:20-1:80) in 62 
the CrAgSQ2+ category; 1:640 (IQR 1:160-1:2560) in the CrAgSQ3+ category; and 1:5120 (IQR 1:2560-63 
1:30720) in the CrAgSQ4+ category. Increasing CrAgSQ scores were strongly associated with 10-week 64 
mortality. 65 
 66 
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Conclusions: The CrAgSQ test had high sensitivity and specificity compared to the IMMY CrAg LFA test 67 
and provided CrAg scores associated with both conventional CrAg titers and clinical outcomes. 68 
  69 
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INTRODUCTION 70 
Cryptococcal meningitis is a major cause of morbidity and mortality among people living with HIV 71 
(PLWH), resulting in an estimated 15% of HIV-related deaths worldwide (1). The incidence of HIV-72 
associated cryptococcal meningitis has remained high in many low and middle-income settings despite 73 
improved population-level access to antiretroviral therapy (ART) (1-3). Mortality rates from cryptococcal 74 
meningitis with currently available treatments also remain unacceptably high, ranging from 25%-45% at 75 
ten weeks (4-7). There is an urgent need to improve both prevention and treatment strategies (8, 9).  76 
Detection of the cryptococcal capsular polysaccharide antigen glucuronoxylomannan (GXM), commonly 77 
known as cryptococcal antigen (CrAg), in body fluids including cerebrospinal fluid (CSF) and blood (whole 78 
blood, plasma, or serum) is the cornerstone of diagnosis. Highly sensitive and specific CrAg lateral flow 79 
assays (LFAs) (10, 11), appropriate for use in laboratories with limited facilities or at the point of care 80 
(12), have markedly facilitated rapid clinical diagnosis of cryptococcal meningitis, and also enabled the 81 
implementation of CrAg screening programs aimed at detecting and treating early asymptomatic 82 
infection in HIV-positive individuals with low CD4 T-cell counts (13-16). In addition to providing a 83 
qualitative (positive/negative) result, higher CrAg titers have been shown to be strongly associated with 84 
increased fungal burden and mortality risk in patients with cryptococcal meningitis (17), and with the 85 
presence of central nervous system (CNS) infection and mortality risk among asymptomatic CrAg-86 
positive individuals identified through (blood/plasma) CrAg screening programs (2, 18, 19). Determining 87 
CrAg titers may therefore provide important prognostic information, enabling stratification of treatment 88 
in individuals with cryptococcal meningitis, and identification of the CrAg-positive individuals detected 89 
through CrAg screening programs who require lumbar puncture (LP) to rule out CNS infection or may 90 
benefit from more intensive antifungal therapy.  91 
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Currently-used commercial CrAg assays provide a qualitative dichotomous positive/negative result, 92 
necessitating the testing of serial dilutions of the primary specimen to obtain a quantitative titer result. 93 
This serial testing involves significant additional costs, is time-intensive, and requires laboratory 94 
operator expertise which limits performance in clinical practice, and therefore it is rarely performed in 95 
low resource settings. To overcome these limitations, IMMY (Norman, OK, USA) has developed a new 96 
immunochromatographic test system for the semi-quantitative detection of the capsular polysaccharide 97 
antigens of the Cryptococcus neoformans/gattii species complex in serum, plasma, whole blood, and CSF 98 
(the “CrAgSQ” LFA) (Figure 1). We performed a comprehensive laboratory-based validation study to 99 
evaluate the performance of the CrAgSQ assay against the current gold-standard CrAg detection tests, 100 
assessing the diagnostic accuracy of the CrAgSQ assay in HIV-positive individuals undergoing CrAg 101 
screening; determining the relationship of CrAgSQ band cut-offs with conventionally-derived CrAg titers; 102 
assessing inter-rater reliability to inform interpretability of the CrAgSQ assay; and determining clinical 103 
correlates of CrAgSQ results.  104 
 105 
METHODS 106 
Study Population and procedures. 107 
The study was performed in two parts (Figure 2). In the first part, the qualitative (positive / negative) 108 
performance of the CrAgSQ assay was evaluated against the first-generation qualitative IMMY CrAg LFA 109 
in a consecutively-recruited cohort of HIV-positive individuals with CD4 cell counts ≤200 cells/µL 110 
undergoing reflex CrAg screening at the Botswana-Harvard HIV Reference Laboratory (BHHRL) in 111 
Gaborone, Botswana, between January and August 2018 (“cohort 1”). BHHRL performs almost all CD4 112 
testing for 27 public ART clinics and a national referral hospital in greater Gaborone. Residual EDTA 113 
whole blood sent to the BHHRL for routine CD4 testing found to have a CD4 ≤200 cells/µL underwent 114 
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CrAg screening using the IMMY CrAg LFA as part of a reflex CrAg screening study. The IMMY CrAg LFA is 115 
an immunochromatographic CrAg test that provides a qualitative test result within 15 minutes. The 116 
assay has been extensively validated on whole blood, serum, plasma, and CSF samples and is highly-117 
accurate compared to other commercial assay types such as available enzyme immunoassays (EIAs) (10, 118 
11). Plasma was separated and stored in -80C freezers at the Botswana National Health Laboratory for 119 
subsequent CrAgSQ testing and IMMY CrAg LFA titer determination on completion of study recruitment. 120 
The sensitivity and specificity of the CrAgSQ were determined against the IMMY CrAg LFA as a reference 121 
standard, with all positive CrAgSQ scores (1+, 2+, 3+, 4+, or 5+) considered positive.  122 
The second part of the study evaluated the relationship between CrAgSQ semi-quantitative results 123 
(CrAgSQ “score”) and (a) IMMY CrAg LFA titers, and (b) clinical outcome (CNS disease in the CrAg 124 
screened population, and 10-week mortality in all cases). These assessments were performed using the 125 
plasma samples from cohort 1 described above, plus a collection of stored frozen plasma samples that 126 
had previously tested CrAg-positive using the IMMY CrAg LFA (“cohort 2”). Cohort 2 consisted of all 127 
plasma samples with positive CrAg tests from a 2015-2016 CrAg screening cohort study performed at 128 
BHHRL (2, 20) and from a phase II randomized-controlled trial (RCT) evaluating cryptococcal meningitis 129 
therapies in Gaborone, Botswana (21).  130 
All CrAgSQ assays were performed by trained laboratory technicians according to manufacturer’s 131 
instructions and read by two independent laboratory technicians blinded to previous CrAg test results as 132 
well as the other technician’s read. Results were recorded as negative or 1+, 2+, 3+, 4+, or 5+ (Figure 1). 133 
The CrAgSQ test turn around time is approximately 15 minutes, similar to the conventional IMMY LFA 134 
test, and relies on a visual reading of line color intensity thus is subject to a degree of operator 135 
dependency. Discordant reads between technicians were arbitrated by a third investigator and a 136 
photographic record of all test strips maintained (see supplementary materials). Samples with 137 
discrepant qualitative results from the IMMY LFA and CrAgSQ assays, i.e. one positive and the other 138 
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negative, were re-tested at an independent accredited laboratory using a commercial enzyme 139 
immunoassay (EIA) [IMMY, Norman, OK, USA] by a scientist blinded to previous results.  140 
Patients identified as CrAg-positive during the CrAg screening studies were treated according to an 141 
algorithm based on World Health Organization (WHO) guidelines [9,11], recommending high-dose 142 
fluconazole (1200mg/day) for asymptomatic individuals, LP to rule out CNS infection, and referral for 143 
amphotericin B-based treatment as an inpatient if CSF CrAg-positive (supplementary material figure s1). 144 
In the 2015-16 screening study, management decisions were at the discretion of the patients’ healthcare 145 
providers, and the research team had no direct patient contact, thus were unable to directly assess 146 
adherence to treatment guidelines. In the 2018 screening study the research team actively managed 147 
CrAg-positive patients. Patient follow-up data were collected to six-months. The phase II RCT has been 148 
described in detail elsewhere (21). Participants were treated with either amphotericin B deoxycholate or 149 
liposomal amphotericin B, both given with fluconazole, as inpatients, and actively followed-up to ten 150 
weeks. 151 
The research was approved by Institutional Review Boards at the University of Botswana, the Botswana 152 
Ministry of Health and Wellness, and the University of Pennsylvania. As the two CrAg screening studies 153 
were limited to implementation of a laboratory-based, WHO-endorsed screening intervention, and 154 
collection of routine clinical and outcomes data, a waiver of informed patient consent was granted. All 155 
patients in the phase II treatment trial provided written informed consent providing permission for 156 
sample storage and testing.  157 
Validation study analysis 158 
Sensitivity and specificity: Using cohort 1, we calculated the sensitivity, specificity, positive and negative 159 
predictive values of the CrAgSQ assay for qualitative (positive/negative) CrAg detection in plasma using 160 
the first-generation IMMY LFA test as the reference standard. In order to better classify potential false-161 
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positive and false-negative results, an additional analysis was performed in which the IMMY EIA test 162 
result was used as a “tie-breaker” for samples with discrepant test results between the CrAgSQ assay 163 
and IMMY CrAg LFA, and the reference test result reclassified accordingly. Sensitivity, specificity, 164 
positive and negative predictive values were recalculated against this tie-breaker adjusted composite 165 
reference standard.  166 
Inter-rater reliability: We assessed inter-rater reliability for the CrAgSQ assay using all samples from 167 
cohort 1 and cohort 2. Percent agreement between the two reading technicians was determined using 168 
an unadjusted Cohen’s Kappa statistic. As the CrAgSQ test has ordered categorical values we calculated 169 
a second weighted Kappa with 75% weight given to values that were within 1 category between the two 170 
reviewers, (e.g. readings of 3+ and 4+), 50% weight given to values within 2 categories, 25% weight 171 
within 3 categories, and 0% weighting for a discrepancy of four categories (22).  172 
Association between CrAgSQ quantification and CrAg titers: To evaluate the associations between semi-173 
quantitative CrAgSQ results and CrAg titer values, median CrAg titers were calculated in each CrAgSQ 174 
result category using all samples form cohorts 1 and 2, and the results displayed graphically.  175 
Relationship between CrAgSQ results and clinical outcomes: The proportion of CrAg-screened individuals 176 
with confirmed CNS infection (cryptococcal meningitis) at baseline in cohort 1 and 2 (excluding those in 177 
the phase II treatment trial), and the overall proportion of individuals who died by ten weeks were 178 
calculated according to plasma CrAgSQ category, and the association between plasma CrAgSQ result and 179 
ten-week mortality examined using a Cox proportional hazards model. A sensitivity analysis was 180 
performed in which all individuals lost to follow-up were assumed to have died. 181 
All analyses were performed using STATA version 14 (Stata Corporation, College station, TX). P-values of 182 
<0.05 were considered significant.  183 
 184 
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RESULTS 185 
A total of 872 plasma samples were tested using both the CrAgSQ and IMMY CrAg LFA tests; 692 from 186 
cohort 1 and 180 from cohort 2 (Figure 2). Baseline characteristics of the study participants are shown in 187 
Table 1. Inter-rater agreement in CrAgSQ reading was excellent, with 98.2% agreement, Cohen’s Kappa 188 
0.96, p<0.001 (Table 2A and 2B).  189 
Of the 692 samples tested in the sequentially-enrolled cohort 1, 43 (6.2%) were positive for CrAg using 190 
the IMMY CrAg LFA. Compared to the IMMY CrAg LFA as a reference standard, CrAgSQ (used as a 191 
qualitative test) was 93.0% sensitive (95% confidence interval [CI] 80.9% – 98.5%) and 93.8% specific 192 
(95% CI 91.7% – 95.6%) (Table 2D). Forty of the 649 (6.2%) IMMY CrAg LFA negative samples were 193 
positive on CrAgSQ testing, all at the lowest 1+ score, and classified as false-positive; 3 of the IMMY CrAg 194 
LFA positive samples (all with the lowest titer of 1:2) were negative on CrAgSQ testing, and classified as 195 
false-negative.  196 
On EIA testing, 13 of the 40 CrAgSQ “false-positive” samples were found to be CrAg positive with EIA 197 
readings above the optical density cut-off of 0.265 as specified by the manufacturer, thus reclassified as 198 
true-positives; and 2 of the 3 CrAgSQ “false-negatives” were negative on EIA testing, thus reclassified as 199 
true-negatives (Figure 3). Following this adjustment to the reference standard, the sensitivity of the 200 
CrAgSQ was 98.1% (95% CI 90.1 – 100%), and the specificity was 95.8% (95% CI 99.1% - 100%); 27 (4.2%) 201 
of IMMY CrAg LFA|EIA negative samples were CrAgSQ positive, all at the lowest 1+ score, and classified 202 
as false-positive; 1 of the IMMY CrAg LFA|EIA positive samples (at the lowest titer of 1:2) was negative 203 
on CrAgSQ testing, and classified as false-negative. Detailed clinical information for these unreconciled 204 
discordant results (27 false-positives and 1 false-negative) are shown in supplementary table 1.  205 
Combining all 223 CrAg-positive plasma samples from cohort 1 (n=43) and cohort 2 (n=180), median 206 
CrAg titers were 1:10 (IQR 1:5 – 1:20) in the CrAgSQ 1+ category; 1:40 (IQR 1:20 – 1:80) in the CrAgSQ 2+ 207 
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category; 1:640 (IQR 1:160 – 1:2560) in the CrAgSQ 3+ category; and 1:5120 (IQR 1:2560 – 1:30720) in 208 
the CrAgSQ 4+ category (Figure 3).  209 
Among the 189 CrAgSQ-positive patients included in the two CrAg screening studies (excluding the 210 
cryptococcal meningitis patients enrolled in the treatment trial) the prevalence of CNS involvement at 211 
baseline was strongly associated with CrAgSQ score. Cryptococcal meningitis was confirmed at baseline 212 
in 3.8% (3/80) in the CrAgSQ 1+ category, 17.7% (3/17) in the 2+ category, 16.7% (12/72) in the 3+ 213 
category, and 80% (16/20) in the 4+ category, p-value for trend <0.001 (Figure 4); it is important to note 214 
that these are minimum estimates as LP was only performed in approximately one third of patients 215 
(primarily because patients declined the investigation), and possibly performed more frequently in those 216 
with symptoms of CNS disease. CrAgSQ score was also strongly associated with mortality. Overall in the 217 
combined cohorts 1 and 2, 10 week mortality was 2.0% (11/554) in CrAgSQ-ve individuals; 5.1% (4/78) in 218 
those with CrAgSQ 1+ scores; 11.8% (2/17) with CrAgSQ 2+ scores; 18.8% (16/85) with CrAgSQ 3+ 219 
scores; and 45.2% (19/42)with CrAg 4+ scores (Table 3), p<0.0001. Restricting analysis to participants in 220 
the two CrAg screening studies (excluding the cryptococcal meningitis patients enrolled in the treatment 221 
trial), 10 week mortality was 2.0% (11/554) in CrAgSQ-ve individuals; 2.9% (2/68) in those with CrAgSQ 222 
1+ scores; 13.3% (2/15) with CrAgSQ 2+ scores; 16.1% (9/56) with CrAgSQ 3+ scores; and 53.3% (8/15) 223 
with CrAg 4+ scores (Table 3), p<0.001. Findings in sensitivity analyses where those lost to follow-up 224 
were assumed to have died were unchanged (Table 3). 225 
 226 
DISCUSSION 227 
The novel CrAgSQ semi-quantitative CrAg assay had high sensitivity and specificity when compared to 228 
the current gold-standard CrAg LFA test. Inter-rater agreement in reading the semi-quantitative results 229 
was excellent, and the test provided rapid and reliable estimation of CrAg titers. Increasing CrAgSQ 230 
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scores were strongly associated with presence of CNS involvement in CrAg-positive individuals identified 231 
through CrAg screening programs, and with acute mortality.  232 
The role of CrAg titers in guiding clinical management of HIV-positive patients with asymptomatic 233 
cryptococcal antigenemia identified through CrAg screening programs and in those with overt clinical 234 
cryptococcal meningitis has yet to be defined. Accumulating clinical data suggests that quantification of 235 
CrAg levels using tests such as the CrAgSQ could enable stratification of patients into differentiated 236 
diagnostic and treatment pathways. Recent data from CrAg screening programs in Africa have shown 237 
that asymptomatic CrAg-positive individuals with CD4 cell counts below 200 cells/µL have mortality 238 
rates two- to three-fold higher than their CrAg-negative counterparts with similar CD4 counts (2, 23, 24), 239 
despite treatment with high dose oral fluconazole therapy as recommended in WHO guidelines (16). 240 
This is likely to be due in part to the presence of CNS disease, detectable by LP and CSF evaluation, in 241 
approximately one-third of asymptomatic CrAg-positive patients with advanced HIV (18) for which 242 
fluconazole monotherapy is likely to be insufficient to effectively clear infection (25, 26). However, even 243 
CrAg-positive individuals without CNS involvement at baseline have been shown to progress to 244 
cryptococcal meningitis and death despite high dose fluconazole therapy (27), suggesting that a 245 
proportion of CrAg-positive patients without overt CNS disease may benefit from the intensified 246 
antifungal regimens recommended for the treatment of cryptococcal meningitis (16, 28). Conversely, it 247 
is well established that a sizeable proportion of asymptomatic CrAg-positive individuals identified 248 
through screening programs (approximately 50%) can clear their cryptococcal antigenemia with 249 
effective ART induced immune reconstitution alone (13).  250 
Identifying which CrAg-positive individuals require investigation for CNS disease and / or more intensive 251 
antifungal therapy regimens, and who can be managed effectively with oral fluconazole alone, is 252 
therefore a critical question for CrAg screening programs (16). Elevated CrAg titers of >1:160 have been 253 
shown to be highly predictive of prevalent CNS disease at the time of CrAg screening (with a sensitivity 254 
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of 88% and specificity of 82%) in a study from South Africa (18), with similar findings reported in Ethiopia 255 
(29). Elevated CrAg titers of ≥1:80 or ≥1:160 have also been shown to be strongly associated with 256 
increased risk of mortality in CrAg-positive populations (2, 19). Our findings that higher CrAgSQ antigen 257 
quantification scores are strongly associated with both CNS involvement at baseline in CrAg-positive 258 
individuals, and with higher mortality at ten weeks, add to the already compelling evidence that CrAg 259 
titer data could be used to risk stratify CrAg-positive individuals and guide treatment. Although further 260 
data are required to inform definitive clinical guidelines, a preliminary suggestion based on our data 261 
could be that individuals with a CrAgSQ 1+ score, in whom the risk of baseline CNS involvement and 262 
acute mortality is very low could be managed as per current guidelines with high dose fluconazole and 263 
ART alone, without the need for LP. Those with CrAgSQ scores of 2+ to 3+ could undergo more intensive 264 
clinical evaluation and / or receive more intensive antifungal therapy, for example a combination of 265 
fluconazole and flucytosine (4); whilst those with CrAgSQ scores of 4+, who are at extremely high risk of 266 
CNS disease and mortality, could be admitted for inpatient evaluation and treatment. Such stratification 267 
would enable a large proportion of CrAg-positive individuals to be easily managed as outpatients (43% 268 
[80/189] of CrAg-positive individuals from the screening studies included in our analysis had a CrAgSQ 269 
1+ score), and intensive management to be focused on the smaller proportion of individuals at very high 270 
risk of complications to reduce the high mortality currently observed in this patient population. 271 
Risk stratification based on CrAg quantification to guide differentiated care in patients presenting with 272 
clinical cryptococcal meningitis may also be possible. Extensive data show the strong association 273 
between higher baseline CrAg titers in both blood and CSF and subsequent mortality in patients 274 
undergoing treatment for HIV-associated cryptococcal meningitis. As new all-oral (4) and short course 275 
(4, 21) treatment regimens for cryptococcal meningitis are developed, CrAg quantification could be used 276 
to define a patient population who could be discharged from hospital early, or be treated in ambulatory 277 
 o
n
 June 3, 2020 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
IMMY SQ Evaluation V1.3  20 May 2020 
 14 
settings. Those with higher titers may be candidates for future adjuvant treatments (30), or longer 278 
courses of therapy. 279 
Our study provides the first evidence for the diagnostic performance of the CrAgSQ in a CrAg screening 280 
program targeting individuals with CD4 cell counts ≤200 cells/µL, and also provides information to guide 281 
the interpretation of CrAg SQ scores in HIV-infected patients with cryptococcal infection. However, the 282 
utility of stratifying patient management based on these scores requires further evaluation in 283 
prospective trials. While we have shown associations between CrAgSQ score and the key clinical 284 
variables of CNS disease and mortality, our analysis is limited by the relatively low levels of investigation 285 
for CNS disease at baseline, and a lack of detailed information regarding adherence to treatment 286 
guidelines in the CrAg-positive outpatient population. Our analysis is also unable to provide any 287 
information regarding the potential impacts of introducing alternative management strategies according 288 
to CrAg based risk stratification, or the cost-effectiveness of these strategies. Although not yet 289 
confirmed, preliminary information from IMMY suggest the CrAgSQ test will cost in the range of US$5-6. 290 
Finally, the CrAgSQ test identified some patients as positive at 1+ who had negative IMMY CrAg LFA and 291 
EIA results. While we have classified these as false positive, further CSF and clinical outcome data on this 292 
group are needed in order to determine whether such results represent early cryptococcal infection or 293 
not. Many of these false positive samples had EIA optical density readings above zero but below the 294 
suggested cut-off, which may represent very low levels of cryptococcal antigenemia. A degree of 295 
disparity in test results is inevitable in samples with very low concentrations of the antigen at or near 296 
the limit of detection. Notably, none of the patients with positive CrAg SQ and negative IMMY CrAg LFA 297 
results developed cryptococcal disease, despite not receiving any antifungal therapy, suggesting that 298 
even if the do represent very low CrAg titers, they are of limited clinical significance in individuals who 299 
initiate effective antiretroviral therapy. 300 
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In conclusion, the semi-quantitative CrAgSQ cryptococcal antigen test had high sensitivity and specificity 301 
compared to current IMMY CrAg LFA test and provided quantitative CrAg results which were associated 302 
with both CrAg titers derived from dilutional testing and clinical outcomes. The test provides an effective 303 
and practical method to stratify CrAg-positive patients according to CrAg levels and could provide the 304 
basis for differentiated management approaches to reduce the high mortality seen in HIV-positive 305 
patients with cryptococcal infection. 306 
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Tables 437 
Table 1. Baseline characteristics of study participants 438 
Variable Value (median, IQR or %, n) 
Cohort 1. Sequential cohort of individuals with CD4 cell counts ≤200 cells/µL screened for CrAg 
(n=638)* 
Age (years) 40 years (IQR 33-46) 
Sex (% male) 57% (n=365) 
CD4 count (cells/µL) 91 cells/µL (IQR 53-150) 
Cryptococcal antigenemia† (% positive) 5.8% (n=37) 
Testing location (% outpatients) 88% (n=563) 
ART status§ (% on ART) 71% (n=451) 
Prior cryptococcal meningitis (%) 2% (n=13) 
Cohort 2. Titer validation cohort (all CrAg-positive, n=180)** 
Age (years) 39 years (IQR 34-44) 
Sex (% male) 59% (n=104) 
CD4 count (cells/µL) 41 cells/µL (IQR 16-85) 
Cryptococcal antigenemia† (% positive) 100% (n=180) 
Testing location (% outpatients) 49% (n=88) 
ART status§§ (% on ART) 46% (n=82) 
Prior cryptococcal meningitis (%) 12% (n=21) 
IQR: inter-quartile range; n: number; CrAg: cryptococcal antigen; ART: antiretroviral therapy 
*Sequential samples from individuals with CD4 cell counts ≤200 cells/µL tested during a reflex CrAg 
screening program.  
†Cryptococcal antigen positive using the IMMY [IMMY, Norman, OK, USA] lateral flow assay. 
§ 451/638 (71%) on ART, 32/638 (5%) defaulted ART, 155/638 (24%) ART naïve. Viral loads were 
available for 448 of those on ART, or whom 168 (38%) had a detectable viral load. 
§§ 82/180 (46%) on ART, 13/180 (7%) defaulted ART, 85/180 (47%) ART naïve. Viral loads were 
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available for 55 of those on ART, of whom 16 (29%) had a detectable viral load. 
**The CrAg validation cohort (cohort 2) consisted of 111 known CrAg-positive plasma samples from 
reflex cryptococcal antigen screening studies and 69 plasma samples from patients with cryptococcal 
meningitis enrolled in a clinical trial (n=180 total). 
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Table 2. Diagnostic performance of the IMMY semi-quantitative cryptococcal lateral flow assay  440 
A. Inter-rater agreement 
  Rater B  
  0 1+ 2+ 3+ 4+ Total 
Rater A 
0 610 0 0 0 0 610 
1+ 4 87 0 0 0 91 
2+ 0 3 15 0 0 18 
3+ 0 0 4 101 5 110 
4+ 0 0 0 0 43 43 
 Total 614 90 19 101 48 872 
B. Inter-rater reliability (Cohen’s Kappa Statistic) 
Expected 
agreement 
Observed 
agreement 
Kappa Standard error p-value 
52.11% 98.17% 0.962 0.022 <0.0001 
C. Weighted* inter-rater reliability (Cohen’s Kappa Statistic) 
Expected 
agreement 
Observed 
agreement 
Kappa Standard error p-value 
72.07% 99.54% 0.983 0.028 <0.0001 
*To account for the ordered categorical data and assess the degree of disagreement, disagreements 
were weighted in a linear way; with five categories, cases in adjacent categories were weighted by 
factor 0.75, those with a distance of two categories weighted 0.5, those with a distance of three 
categories weighted 0.25, and those with a distance of four categories weighted 0.  
D. Sensitivity, specificity, positive, and negative predictive value of the IMMY semi-quantitative LFA 
(CrAgSQ) versus the conventional IMMY LFA test† 
  IMMY LFA +ve IMMY LFA -ve Total 
 CrAgSQ +ve 40 40 80 
 CrAgSQ -ve 3 609 612 
 Total 43 649 692 
Sensitivity 93.0% 95% CI 80.9% - 98.5% 
Specificity 93.8% 95% CI 91.7% - 95.6% 
Positive predictive value 50.0% 95% CI 38.6% - 61.4% 
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Negative predictive value 99.5% 95% CI 98.6% - 99.9% 
E. Sensitivity, specificity, positive, and negative predictive value of the IMMY semi-quantitative LFA 
(CrAgSQ) versus the conventional IMMY LFA test after reconciliation of discordant tests§ using EIA 
testing 
  CrAg +ve CrAg -ve Total 
 CrAgSQ +ve 53 27 80 
 CrAgSQ -ve 1 611 612 
 Total 54 638 692 
Sensitivity 98.1% 95% CI 90.1% - 100% 
Specificity 95.8% 95% CI 93.9% - 97.2% 
Positive predictive value 66.3% 95% CI 54.8% - 76.4% 
Negative predictive value 99.8% 95% CI 99.1% - 100% 
IMMY: IMMY, Norman, OK, USA ; LFA: lateral flow assay; CrAgSQ: semi-quantitative LFA; EIA: [ADD] 441 
†All CrAgSQ results of 1+ and above were considered positive. The conventional IMMY qualitative lateral 442 
flow assay was considered the reference test. 443 
§ All CrAgSQ results of 1+ and above were considered positive. The reference standard was a composite 444 
cryptococcal antigen result derived from the conventional IMMY qualitative lateral flow assay with 445 
discrepant LFA/SQ results reconciled using the IMMY EIA as the tie-breaker test. See Figure 1 for details. 446 
 447 
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Table 3. Associations between IMMY semi-quantitative cryptococcal lateral flow assay titers and 449 
mortality 450 
A. All participants (cohorts 1 and 2) 
CrAgSQ Titer Mortality* Hazard Ratio† 95% Confidence Interval p-value 
0 2.0% (11/554) Base -- 
<0.0001 
1+ 5.1% (4/78) 2.63 0.84 - 8.26 
2+ 11.8% (2/17) 6.26 1.39 – 28.25 
3+ 18.8% (16/85) 10.18 4.73 – 21.95 
4+ 45.2% (19/42) 28.85 13.70 – 60.75 
CrAgSQ Titer Dead or lost to 
follow-up§ 
Hazard Ratio† 95% Confidence Interval p-value 
0 4.9% (28/571) Base -- 
<0.0001 
1+ 6.3% (5/79) 1.29 0.50 – 3.34 
2+ 11.8% (2/17) 2.45 0.59 – 10.31 
3+ 19.8% (17/86) 4.12 2.30 – 7.67 
4+ 52.1% (25/48) 14.1 8.19 – 24.17 
B. Participants in CrAg screening studies 
CrAgSQ Titer Mortality* Hazard Ratio† 95% Confidence Interval  
0 2.0% (11/554) Base -- 
<0.0001 
1+ 2.9% (2/68) 1.75 0.50 – 6.13 
2+ 13.3% (2/15) 5.70 1.29 – 25.27 
3+ 16.1% (9/56) 6.85 3.00 – 15.62 
4+ 53.3.% (8/15) 31.80 13.01 – 77.31 
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CrAgSQ Titer Dead or lost to 
follow-up§ 
Hazard Ratio† 95% Confidence Interval  
0 4.9% (28/571) Base --  
1+ 4.4% (3/69) 0.97 0.35 – 2.77  
2+ 13.3% (2/15) 2.38 0.57 – 9.94  
3+ 17.5% (10/57) 3.11 1.57 – 6.20  
4+ 65.0% (13/20) 18.33 9.54 – 35.22  
IMMY: IMMY, Norman, OK, USA; CrAgSQ: semi-quantitative lateral flow assay 451 
*Mortality at 10 weeks. Loss to follow-ups censored. 452 
†Derived from Cox proportional hazards model. 453 
§Dead or lost to follow-up at 10 weeks. Twenty-five patients (3%) were lost to follow-up prior to 10 454 
weeks. 455 
 456 
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Figure Legend 458 
Figure 1. The IMMY semi-quantitative CrAgSQ lateral flow assay (IMMY, Norman, OK, USA). Samples are 459 
diluted 1:1 with specimen diluent prior to testing (as is also the case with the conventional lateral flow 460 
assay). Scores indicating increasing cryptococcal antigen titers are derived from line intensity patterns as 461 
follows: T1<T2 = 1+; T1=T2 = 2+; T1>T2 = 3+; only T1 = 4+; only C = 5+. Only T2 and C = negative. A score 462 
of 1+ indicates “low positive”, and a score of 5+ “very high positive”. 463 
 464 
Figure 2. Schema of plasma samples and patient populations used in the diagnostic validation study. 465 
 466 
Figure 3. Relationship between CrAgSQ scores and cryptococcal antigen titers derived from serial 467 
dilutional testing with the IMMY lateral flow assay (Panel 1). Samples with discordant CrAgSQ and IMMY 468 
lateral flow assay positive / negative results were retested using the IMMY cryptococcal antigen enzyme 469 
immunoassay (EIA) (panel 2). Box A indicates samples that were positive on IMMY lateral flow assay 470 
testing and negative on CrAgSQ testing. Three of these four samples were negative on EIA testing at the 471 
optical density cut off of 0.265. Box B indicates the samples that were positive on CrAgSQ testing and 472 
negative on IMMY lateral flow assay testing. Thirteen of the forty samples were positive on EIA testing 473 
at the optical density cut off of 0.265. 474 
 475 
Figure 4. Associations between CrAgSQ score and A) baseline CNS disease (defined as positive 476 
cerebrospinal fluid CrAg) in the 189 CrAg-positive patients identified through reflex cryptococcal antigen 477 
screening; B) ten-week mortality in all participants; and C) ten-week mortality and loss to follow-up. 478 
Note that only 32% of CrAg-positive individuals underwent baseline CSF examination, thus these figures 479 
represent minimum estimates of baseline CNS disease. 480 
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Figures 482 
Figure 1 483 
 484 
 485 
  486 
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Figure 2 487 
  488 
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Figure 3 489 
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Figure 4 492 
 493 
 494 
 495 
 496 
 497 
 498 
-ve 1+ 2+ 3+ 4+
0
10
20
30
40
50
60
70
80
90
100
IMMY SQ Titer
%
 w
it
h
 m
e
n
in
g
iti
s
CNS involvement
-ve 1+ 2+ 3+ 4+
0
10
20
30
40
50
60
70
80
90
100
IMMY SQ Titer
%
 m
o
rt
a
lit
y
Mortality at 10 weeks
-ve 1+ 2+ 3+ 4+
0
10
20
30
40
50
60
70
80
90
100
IMMY SQ Titer
%
 d
e
a
d
 o
r 
lo
s
t 
to
 f
o
llo
w
-u
p
Death or Loss to follow-up at 10 weeks
A B C
 o
n
 June 3, 2020 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
 o
n
 June 3, 2020 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
 o
n
 June 3, 2020 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
0 1+ 2+ 3+ 4+
Negative
1:1
1:2
1:5
1:10
1:40
1:160
1:640
1:2,560
1:10,240
1:40,960
1:163,840
1:655,360
IMMY SQ Result
L
o
g
2
 C
rA
g
 T
ite
r
1:160
SQ -ve / LFA +ve SQ +ve / LFA -ve
0.0
0.2
0.4
0.6
0.8
1.0
C
rA
g
 E
IA
 O
D
 R
e
s
u
lt 
(u
n
its
) 
A
B
A
B
Panel 1.
Panel 2.
 o
n
 June 3, 2020 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
-ve 1+ 2+ 3+ 4+
0
10
20
30
40
50
60
70
80
90
100
IMMY SQ Titer
%
 w
ith
 m
e
n
in
g
iti
s
CNS involvement
-ve 1+ 2+ 3+ 4+
0
10
20
30
40
50
60
70
80
90
100
IMMY SQ Titer
%
 m
o
rt
a
lit
y
Mortality at 10 weeks
-ve 1+ 2+ 3+ 4+
0
10
20
30
40
50
60
70
80
90
100
IMMY SQ Titer
%
 d
e
a
d
 o
r 
lo
s
t 
to
 f
o
llo
w
-u
p
Death or Loss to follow-up at 10 weeks
A B C
 o
n
 June 3, 2020 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
